A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Clinical trial NCT06970743 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06970743
- Sponsor
- BeOne Medicines
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-29
- Primary completion
- 2029-11-30
- Enrollment
- 153
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.